IOBT Competitors

Stocks . USA . 
Stock . IO Biotech
IOBT Stock  USD 1.93  0.02  1.03%   
IO Biotech competes with Molecular Partners, Galecto, Centessa Pharmaceuticals, Edgewise Therapeutics, and Xilio Development; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing IO Biotech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of IO Biotech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out IO Biotech Correlation with its peers.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of IO Biotech competition on your existing holdings.
  
Build AI portfolio with IOBT Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.101.937.48
Details
Intrinsic
Valuation
LowRealHigh
0.071.446.99
Details
Naive
Forecast
LowNextHigh
0.052.267.81
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.081.582.08
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as IO Biotech. Your research has to be compared to or analyzed against IO Biotech's peers to derive any actionable benefits. When done correctly, IO Biotech's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in IO Biotech.

IO Biotech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between IO Biotech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of IOBT and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of IO Biotech does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HOWL
+ 0.72
GLTO
CLYM
+ 0.6
GLTO
CLYM
+ 0.55
CNTA
CLYM
+ 0.53
HOWL
XLO
+ 0.41
MOLN
CNTA
+ 0.4
GLTO
  
High negative correlations   
GLTO
- 0.67
MOLN
EWTX
- 0.54
GLTO
HOWL
- 0.51
MOLN
XLO
- 0.48
GLTO
CLYM
- 0.46
MOLN
CNTA
- 0.37
MOLN

Risk-Adjusted Indicators

There is a big difference between IOBT Stock performing well and IO Biotech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze IO Biotech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

IO Biotech Competitive Analysis

The better you understand IO Biotech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, IO Biotech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across IO Biotech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IOBT MOLN GLTO CNTA EWTX XLO HOWL CLYM
 1.03 
 1.93 
IOBT
 3.12 
 3.73 
Molecular
 4.40 
 3.80 
Galecto
 3.71 
 15.57 
Centessa
 1.12 
 13.54 
Edgewise
 1.43 
 0.69 
Xilio
 0.71 
 1.39 
Werewolf
 6.62 
 1.41 
Climb
Market Volatility
(90 Days Market Risk)
Dangerous
Moderately volatile
Risky
Somewhat reliable
Not too volatile
Out of control
Abnormally volatile
Dangerous
Market Performance
(90 Days Performance)
Solid
Very Weak
Good
Modest
Very Weak
Weak
Good
Insignificant
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Average
Very High
Quite High
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
20.94 X
14.37 X
10.98 X
15.48 X
27.49 X
9.17 X
5.08 X
N/A
Net Asset
67.7 M
158.53 M
17.13 M
576.8 M
486.82 M
71.08 M
126.93 M
217.19 M
EBITDA
(93.2 M)
(51.65 M)
(21.22 M)
(221.97 M)
(131.52 M)
(58 M)
(64.05 M)
(30.36 M)
Current Valuation
93.14 M
(15.8 M)
(5.69 M)
1.99 B
992.58 M
(44.96 M)
7.8 M
(11.77 M)
Price To Book
5.04 X
0.86 X
0.39 X
5.59 X
3.31 X
3.39 X
1.10 X
0.44 X
Operating Margin
N/A
(27.55) %
N/A
(2.05) %
N/A
(4.73) %
(65.11) %
N/A
Retained Earnings
(359.31 M)
(246.29 M)
(277.52 M)
(988.7 M)
(378.58 M)
(383.75 M)
(414.59 M)
(229.88 M)
Beta
0.37
0.57
1.36
1.45
0.26
-0.12
0.62
-0.11
Number Of Employees
79
158
5
86
117
64
46
17
Shares Outstanding
65.88 M
36.87 M
1.32 M
133.62 M
105.2 M
51.78 M
44.87 M
67.58 M
Cash Flow From Operations
(82.35 M)
(59.25 M)
(18.62 M)
(142.06 M)
(109.03 M)
(18.38 M)
(56.19 M)
(15.56 M)
Total Debt
1.92 M
2.44 M
73 K
117.23 M
4.74 M
8.14 M
37.09 M
532 K
Return On Equity
-1.39
-0.4
-0.88
-0.74
-0.3
-2.98
-0.83
-0.62
Return On Asset
-0.7
-0.24
-0.36
-0.29
-0.21
-0.38
-0.33
-0.19
Number Of Shares Shorted
122.66 K
33.74 K
36.85 K
3.84 M
12.66 M
3.32 M
1.32 M
1.41 M
Book Value Per Share
0.40 X
3.84 X
9.34 X
2.89 X
4.51 X
0.21 X
1.28 X
2.86 X
Total Asset
67.7 M
158.53 M
17.13 M
576.8 M
486.82 M
71.08 M
126.93 M
217.19 M
Debt To Equity
0.01 %
0.02 %
0.01 %
0.16 %
0.01 %
0.14 %
0.12 %
N/A
Short Ratio
0.66 X
13.63 X
1.94 X
3.17 X
12.67 X
3.53 X
2.06 X
14.68 X
Target Price
9.5
11.04
6.0
32.33
38.82
4.0
9.5
10.0
Shares Owned By Institutions
66.45 %
9.72 %
13.02 %
94.39 %
99.58 %
22.99 %
62.74 %
84.98 %
Market Capitalization
128.47 M
145.51 M
4.81 M
2.16 B
1.41 B
36.25 M
62.82 M
85.82 M
Price To Earning
N/A
1.85 X
N/A
N/A
3.45 X
N/A
0.84 X
N/A
Price To Earnings To Growth
N/A
N/A
(0.01) X
N/A
N/A
N/A
(0.06) X
N/A
Price To Sales
N/A
65.19 X
N/A
144.04 X
N/A
3.91 X
54.96 X
N/A
Net Income
(95.49 M)
(54.04 M)
(21.44 M)
(235.76 M)
(133.81 M)
(58.24 M)
(70.52 M)
(73.9 M)
Earnings Per Share
(1.49) X
(2.12) X
(15.40) X
(1.88) X
(1.55) X
(0.65) X
(1.64) X
(1.78) X
Shares Owned By Insiders
0.35 %
N/A
3.68 %
0.50 %
0.42 %
45.76 %
6.07 %
7.95 %
Revenue
N/A
4.97 M
N/A
N/A
N/A
6.34 M
1.89 M
N/A
Working Capital
45.47 M
143.5 M
15.64 M
478.41 M
451.62 M
32.97 M
97.89 M
149.94 M
Cash And Equivalents
170.12 M
267.13 M
79.03 M
484.16 M
248.4 M
159.41 M
145.71 M
N/A
Cash Per Share
5.90 X
8.22 X
3.11 X
5.13 X
4.99 X
5.82 X
4.93 X
N/A
Gross Profit
N/A
(43.09 M)
N/A
15 M
N/A
9.27 M
(52.24 M)
N/A
Day Typical Price
1.95
3.77
3.77
15.86
13.52
0.69
1.41
1.41
Accumulation Distribution
13481.12
0.0312
721.47
86367.35
0.0234
9836.1
8415.42
0.0417
Market Facilitation Index
N/A
0.12
0.0
0.0
0.32
N/A
N/A
0.06
Daily Balance Of Power
(0.25)
(1.00)
0.5714
(0.70)
0.4688
(0.33)
(0.20)
(1.67)
Period Momentum Indicator
(0.02)
(0.12)
0.16
(0.60)
0.15
(0.01)
(0.01)
(0.10)
Rate Of Daily Change
0.99
0.97
1.04
0.96
1.01
0.99
0.99
0.93
Day Median Price
1.96
3.79
3.76
16.0
13.51
0.69
1.42
1.41
Price Action Indicator
(0.04)
(0.12)
0.12
(0.73)
0.1
N/A
(0.03)
(0.05)
Relative Strength Index
66.98
48.53
60.4
59.44
46.24
46.47
60.92
55.04
Coefficient Of Variation
411.82
2743.54
693.26
815.7
(2,022)
7679.9
695.22
1935.62
Mean Deviation
4.25
3.02
2.57
2.47
2.2
4.36
4.39
3.22
Jensen Alpha
1.36
0.3393
0.3692
0.0903
(0.34)
0.0907
0.4039
(0.02)
Total Risk Alpha
0.0545
(0.81)
(0.33)
(0.38)
(0.90)
(2.16)
(0.54)
(0.76)
Sortino Ratio
0.2708
(0.02)
0.0738
0.0575
N/A
(0.01)
0.1336
1.0E-4
Downside Variance
17.49
18.55
18.44
11.94
N/A
79.07
24.57
15.63
Standard Deviation
5.55
4.12
3.69
3.38
3.17
9.84
6.1
4.19
Kurtosis
0.7684
0.7941
1.41
1.92
4.59
21.59
3.21
0.2684
Potential Upside
11.76
6.94
6.96
4.85
4.15
7.46
12.12
7.5
Treynor Ratio
(13.08)
(0.14)
0.7014
0.2649
(0.20)
0.8867
0.3849
0.1886
Maximum Drawdown
27.36
22.81
19.14
15.95
19.14
92.11
35.53
20.13
Variance
30.82
16.95
13.63
11.43
10.05
96.8
37.24
17.52
Market Risk Adjusted Performance
(13.07)
(0.13)
0.7114
0.2749
(0.19)
0.8967
0.3949
0.1986
Risk Adjusted Performance
0.2245
0.0403
0.136
0.1165
(0.04)
0.0207
0.1366
0.0539
Skewness
0.8125
(0.02)
(0.34)
(0.39)
(0.95)
2.34
1.25
0.4512
Semi Deviation
3.22
3.73
3.43
3.12
N/A
7.39
4.28
3.44
Information Ratio
0.204
(0.02)
0.0858
0.0588
(0.12)
(0.01)
0.1085
1.0E-4
Value At Risk
(6.14)
(7.01)
(7.59)
(5.35)
(3.95)
(6.67)
(6.92)
(6.35)
Expected Short fall
(6.01)
(3.71)
(3.01)
(2.72)
N/A
(6.28)
(5.41)
(4.06)
Downside Deviation
4.18
4.31
4.29
3.46
N/A
8.89
4.96
3.95
Semi Variance
10.35
13.88
11.74
9.71
N/A
54.61
18.3
11.83

IO Biotech Competition Performance Charts

Five steps to successful analysis of IO Biotech Competition

IO Biotech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by IO Biotech in relation to its competition. IO Biotech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of IO Biotech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact IO Biotech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to IO Biotech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your IO Biotech position

In addition to having IO Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small & Mid Caps ETFs Thematic Idea Now

Small & Mid Caps ETFs
Small & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Small & Mid Caps ETFs theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY